Capital World Investors Has $465.07 Million Stock Position in Hims & Hers Health, Inc. $HIMS

Capital World Investors decreased its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 23.7% during the 4th quarter, HoldingsChannel.com reports. The firm owned 14,322,912 shares of the company’s stock after selling 4,460,282 shares during the period. Capital World Investors owned approximately 0.06% of Hims & Hers Health worth $465,069,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of HIMS. Farallon Capital Management LLC increased its stake in shares of Hims & Hers Health by 30.8% during the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after purchasing an additional 2,533,271 shares during the last quarter. Norges Bank acquired a new position in shares of Hims & Hers Health during the 4th quarter worth $62,153,000. Invesco Ltd. increased its stake in shares of Hims & Hers Health by 62.7% during the 3rd quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock worth $235,525,000 after purchasing an additional 1,600,004 shares during the last quarter. Clear Street Group Inc. acquired a new position in shares of Hims & Hers Health during the 3rd quarter worth $87,372,000. Finally, Vanguard Group Inc. increased its stake in shares of Hims & Hers Health by 7.2% during the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock worth $679,456,000 after purchasing an additional 1,407,651 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Stock Performance

NYSE:HIMS opened at $26.25 on Monday. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18. The firm has a market capitalization of $6.08 billion, a PE ratio of -291.71, a PEG ratio of 49.14 and a beta of 2.37. The firm’s fifty day simple moving average is $24.61 and its 200 day simple moving average is $27.02. Hims & Hers Health, Inc. has a 1 year low of $13.74 and a 1 year high of $70.43.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.44). The company had revenue of $608.10 million during the quarter, compared to analyst estimates of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The business’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.20 earnings per share. On average, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.04 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently commented on HIMS. Weiss Ratings lowered shares of Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a research note on Tuesday, May 12th. Barclays raised their target price on shares of Hims & Hers Health from $25.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, March 11th. Canaccord Genuity Group set a $32.00 target price on shares of Hims & Hers Health in a research note on Tuesday, May 12th. Needham & Company LLC raised their target price on shares of Hims & Hers Health from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $25.00 target price on shares of Hims & Hers Health in a research note on Tuesday, May 5th. Four equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $28.70.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 7,950 shares of the firm’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $23.64, for a total value of $187,938.00. Following the sale, the chief financial officer directly owned 262,954 shares in the company, valued at $6,216,232.56. This trade represents a 2.93% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Michael Chi sold 97,289 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total transaction of $2,402,065.41. Following the completion of the sale, the chief operating officer owned 407,282 shares in the company, valued at $10,055,792.58. This represents a 19.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 212,807 shares of company stock valued at $5,473,644. Company insiders own 11.76% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.